JP2014511884A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511884A5
JP2014511884A5 JP2014505543A JP2014505543A JP2014511884A5 JP 2014511884 A5 JP2014511884 A5 JP 2014511884A5 JP 2014505543 A JP2014505543 A JP 2014505543A JP 2014505543 A JP2014505543 A JP 2014505543A JP 2014511884 A5 JP2014511884 A5 JP 2014511884A5
Authority
JP
Japan
Prior art keywords
pyrazolo
quinolin
methoxy
amine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511884A (ja
JP6278406B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/001736 external-priority patent/WO2012143143A1/en
Publication of JP2014511884A publication Critical patent/JP2014511884A/ja
Publication of JP2014511884A5 publication Critical patent/JP2014511884A5/ja
Application granted granted Critical
Publication of JP6278406B2 publication Critical patent/JP6278406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505543A 2011-04-21 2012-04-23 キナーゼ・インヒビターとしての複素環化合物 Active JP6278406B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161517581P 2011-04-21 2011-04-21
US61/517,581 2011-04-21
PCT/EP2012/001736 WO2012143143A1 (en) 2011-04-21 2012-04-23 Heterocyclic compounds as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014511884A JP2014511884A (ja) 2014-05-19
JP2014511884A5 true JP2014511884A5 (enExample) 2016-10-27
JP6278406B2 JP6278406B2 (ja) 2018-02-14

Family

ID=46001141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505543A Active JP6278406B2 (ja) 2011-04-21 2012-04-23 キナーゼ・インヒビターとしての複素環化合物

Country Status (25)

Country Link
US (1) US9499535B2 (enExample)
EP (1) EP2699572B1 (enExample)
JP (1) JP6278406B2 (enExample)
KR (1) KR101649610B1 (enExample)
CN (1) CN103717597B (enExample)
AP (1) AP2013007252A0 (enExample)
AU (1) AU2012244549B2 (enExample)
BR (1) BR112013026744B1 (enExample)
CA (1) CA2831680C (enExample)
CL (1) CL2013003052A1 (enExample)
CO (1) CO6831983A2 (enExample)
CR (1) CR20130537A (enExample)
CU (1) CU20130144A7 (enExample)
EA (1) EA034193B1 (enExample)
EC (1) ECSP13012984A (enExample)
GT (1) GT201300259A (enExample)
IL (1) IL228967B (enExample)
MA (1) MA35123B1 (enExample)
MX (1) MX365784B (enExample)
PE (1) PE20140927A1 (enExample)
PH (1) PH12013502184A1 (enExample)
SG (1) SG194216A1 (enExample)
TN (1) TN2013000422A1 (enExample)
TW (1) TWI557121B (enExample)
WO (1) WO2012143143A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014060113A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
PL2970333T3 (pl) * 2013-03-15 2017-12-29 Oncodesign S.A. Makrocykliczne inhibitory kinazy LRRK2
WO2015026683A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9801880B2 (en) * 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
DK4001311T3 (da) 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN111514144B (zh) * 2015-05-26 2021-10-26 高雄医学大学 具抑制细菌葡萄糖醛酸酶活性的吡唑并[4,3-c]喹啉衍生物
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
CN105664178B (zh) * 2015-09-24 2019-08-20 洪健 Syk作为肝纤维化/硬化治疗靶点的应用
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
DK3558997T3 (da) 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
AU2018236286B2 (en) * 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
CN108794467A (zh) * 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
FI3641771T3 (fi) 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
WO2019209896A1 (en) * 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP2020132986A (ja) * 2019-02-25 2020-08-31 東京エレクトロン株式会社 成膜用組成物および成膜方法
CN111825694B (zh) * 2019-04-18 2023-08-11 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
KR20220062038A (ko) * 2019-09-13 2022-05-13 오리제니스 게엠베하 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물
KR20220062567A (ko) * 2019-09-13 2022-05-17 오리제니스 게엠베하 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および/または肺傷害を処置するための化合物、組成物および方法
WO2021207141A1 (en) * 2020-04-06 2021-10-14 The Regents Of The University Of Colorado, A Body Corporate METHODS OF USING NEUROKININ-1 RECEPTOR (NK-1R) ANTAGONISTS TO TREAT β-CORONAVIRUS INFECTION INCLUDING SARS-COV-2 INFECTION AND/OR COVID-19 DISEASE
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
BR112023000308A2 (pt) * 2020-07-06 2023-03-28 Acad Of Military Medical Sciences Uso de taurolidina contra vírus
WO2022079250A1 (en) * 2020-10-16 2022-04-21 Merck Patent Gmbh Compounds for the treatment of viral infections
CN112138015B (zh) * 2020-10-22 2022-08-05 合肥博思科创医药科技有限公司 三苄糖苷在治疗微循环障碍引起的皮肤疾病中的应用
US20230392206A1 (en) * 2020-10-26 2023-12-07 Neuron23, Inc. Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2
EP4286386A4 (en) * 2021-02-03 2025-03-12 Ocumension Therapeutics (Suzhou) Co., Ltd. Salt form and crystal form of a pyrazole-substituted imidazo[1,2-a]quinoxaline derivative
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN116808016A (zh) * 2022-01-13 2023-09-29 浙江中医药大学 依普黄酮在抑制炎症小体活化中的应用
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors
CN121731307A (zh) * 2025-11-10 2026-03-27 南通大学附属医院 地舍平在制备治疗泪腺分泌功能障碍相关疾病药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022078B1 (de) 1979-06-21 1984-07-25 Ciba-Geigy Ag Pyrazolochinoline, Verfahren zu ihrer Herstellung, und pharmazeutische Präparate enthaltend diese Verbindungen
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
AR046172A1 (es) 2003-10-03 2005-11-30 3M Innovative Properties Co Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1863813A2 (en) * 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
AU2009257602B2 (en) 2008-06-10 2015-10-08 Abbvie Inc. Novel tricyclic compounds
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
JP2012502067A (ja) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
JP2010143829A (ja) * 2008-12-16 2010-07-01 Dainippon Sumitomo Pharma Co Ltd 新規なイミダゾキノリン誘導体
EP2408772B1 (en) 2009-03-19 2015-07-01 Medical Research Council Technology Compounds
EP4782062A2 (en) 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
JP2013512282A (ja) 2009-12-01 2013-04-11 アボット・ラボラトリーズ 新規三環式化合物
TW201204727A (en) 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors

Similar Documents

Publication Publication Date Title
JP7650854B2 (ja) ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
US10995078B2 (en) Compounds and compositions for inhibition of FASN
AU2017382185C9 (en) Pyrazole derivatives as MALT1 inhibitors
JP2014511885A5 (enExample)
JP5134548B2 (ja) 過剰増殖性疾患の処置のためのErbBI型受容体チロシンキナーゼ阻害剤としてのN4−フェニルキナゾリン−4−アミン誘導体および関連化合物
JP6258331B2 (ja) キナーゼ阻害剤としてのアミノ−キノリン
JP2020514267A5 (enExample)
WO2015171527A1 (en) Pyrazolopyridine pyrazolopyrimidine and related compounds
JP2016500671A5 (enExample)
EP3039021A1 (en) Biaryl acetamide compounds and methods of use thereof
WO2015038417A1 (en) Compounds for regulating fak and/or src pathways
WO2014060113A1 (en) Novel kinase inhibitors
CN119095839A (zh) 作为Mas相关G蛋白受体X2的调节剂和相关产物的喹啉衍生物
TW202529739A (zh) Parg之抑制劑
CA3250387A1 (en) Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors
HK40018685A (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
HK40018685B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
HK1220409B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer